OraSure Technologies, Inc. (NASDAQ:OSUR) Holdings Decreased by Centiva Capital LP

Centiva Capital LP lowered its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 53.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 64,431 shares of the medical instruments supplier’s stock after selling 72,545 shares during the quarter. Centiva Capital LP’s holdings in OraSure Technologies were worth $275,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of OraSure Technologies by 46.4% in the 2nd quarter. SG Americas Securities LLC now owns 17,125 shares of the medical instruments supplier’s stock worth $73,000 after acquiring an additional 5,431 shares during the period. Assenagon Asset Management S.A. boosted its stake in OraSure Technologies by 74.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 163,542 shares of the medical instruments supplier’s stock valued at $697,000 after purchasing an additional 69,625 shares in the last quarter. Acadian Asset Management LLC boosted its stake in OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after purchasing an additional 605,324 shares in the last quarter. Koss Olinger Consulting LLC acquired a new position in shares of OraSure Technologies during the 2nd quarter valued at $327,000. Finally, Factorial Partners LLC raised its stake in shares of OraSure Technologies by 86.3% in the 2nd quarter. Factorial Partners LLC now owns 303,627 shares of the medical instruments supplier’s stock worth $1,293,000 after buying an additional 140,627 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday.

OraSure Technologies Price Performance

NASDAQ OSUR opened at $4.11 on Thursday. OraSure Technologies, Inc. has a 12 month low of $3.72 and a 12 month high of $8.45. The company has a market capitalization of $306.58 million, a P/E ratio of 27.40 and a beta of 0.03. The company’s 50 day simple moving average is $4.03 and its 200 day simple moving average is $4.24.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The company had revenue of $39.92 million for the quarter, compared to analysts’ expectations of $38.97 million. During the same quarter in the prior year, the company earned $0.27 earnings per share. The firm’s revenue was down 55.2% on a year-over-year basis. On average, analysts anticipate that OraSure Technologies, Inc. will post -0.07 earnings per share for the current year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.